Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease

Suggala Ramya Shri ¹ , Suman Manandhar ¹ , Yogendra Nayak ¹ , K Sreedhara Ranganath Pai ¹ *

Cited by CrossRef: 0

1- Turkistani A, Al-kuraishy H, Al-Gareeb A, Albuhadily A, Alexiou A, Papadakis M, Elfiky M, Saad H, Batiha G. Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue. Mol Neurobiol. 2024; [Crossref]

2- Dunlap N, Friedland R, Cai L. Alzheimer's disease and low-dose radiation therapy: A new hope. Radiation Medicine and Protection. 2024;5(1):1 [Crossref]

3- El‐Kadi R, AbdelKader N, Zaki H, Kamel A. Influence of β‐catenin signaling on neurogenesis in neuropsychiatric disorders: Anxiety and depression. Drug Development Research. 2024;85(1) [Crossref]

4- Jitendra Joshi N, Raja Sekhar Reddy A. Navigating the GSK-3β inhibitors as versatile multi-target drug ligands in Alzheimer’s disease intervention – A comprehensive review. Results in Chemistry. 2024;7:101500 [Crossref]